Why this year’s London Tech Week looks set to be the biggest ever May 22, 2024 During London Tech Week, speakers from the government and across industry will focus on the topics du jour, such as the UK's AI ambitions.
London-listed software firm Idox has 20 per cent revenue boost on ‘healthy’ M&A pipeline May 22, 2024 Idox, which sells software property management software to the government, also more than halved its debt to £6.6m, down from £14.7m.
BT fined millions for failing to give customers contract information May 22, 2024 BT refeused to make the changes even after it was told to by the regulator.
Arm to act as cornerstone investor for Raspberry Pi as it confirms intention to float May 22, 2024 London can breathe a sigh of relief as Raspberry Pi has confirmed its intention to IPO on the LSE, following months of teasing the move.
Where are all the UK’s female tech millionaires? May 22, 2024 Research shows that the male-dominated funding ecosystem is holding back female-led tech firms. If the UK wants to become a tech superpower, this has to change, Jess Jones argues
Based in an old Bermondsey biscuit factory, this London cancer drug firm just raised millions May 21, 2024 Founded in 2012 by a PhD student, Labgenius uses technology to create more effective and safer antibodies for cancer treatment.
Donald Trump’s Truth Social craters to $300m loss amid market manipulation claims May 21, 2024 Trump Media and Technology Group's primary asset Truth Social generated just $770,500 in sales over the quarter.
Scarlett Johansson ‘shocked’ over OpenAi’s ‘eerily similar’ ChatGPT voice May 21, 2024 On Sunday, OpenAI announced it was pausing the voice to address "questions about how we chose the voices in ChatGPT."
Greencore: Irish food firm upgrades guidance and launches £30m share buyback scheme May 21, 2024 Greencore has upgraded the range of £80.5m to £85m it said it was expecting for the full year during its first quarter results.
‘New era of growth’: FTSE 100 giant Astrazeneca aims to double revenue May 21, 2024 London-listed Astrazeneca reported revenue of $45.8bn in 2023 and growth of 19 per cent to $12.7bn in the first quarter of 2024.